Qualigen Therapeutics, Inc.

QLGNNASDAQHealthcare

$3.21

+$0.17(+5.59%)

Market Cap$5430810

P/E Ratio—

52W High$8.81

52W Low$1.61

Avg Volume2.6M

Open$2.98

Beta0.28

Insider Trades Ownership Employees

Qualigen Therapeutics, Inc. (QLGN) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · QLGN · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

∞

Buy/Sell (by trades)

Overall sentiment

BULLISH

↑ Buy 100%Active transactions only · RSU vesting excluded0% Sell ↓

Qualigen Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

QLGN insider buying and selling by quarter

QLGN insider selling · QLGN insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

4.4M2.2M0

2020 Q2

2020 Q3

2020 Q4

2021 Q2

2021 Q3

2021 Q4

2022 Q2

2022 Q3

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Recent insider transactions

QLGN executive sell shares · QLGN board member insider trading · QLGN insider trading SEC filing

Showing 18 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Jun 22, 2022	Poirier Michael S. Chairman and CEO	Purchase	30,000	$0.57	$17K	199,202	Form 4
Jun 14, 2022	BROIDRICK AMY S. President/CSO	Purchase	30,000	$0.62	$19K	34,500	Form 4
Aug 19, 2021	Kruger Kurt H Director	Purchase	4,000	$1.22	$5K	18,000	Form 4
Aug 19, 2021	Kruger Kurt H Director	Purchase	4,000	$1.23	$5K	14,000	Form 4
Apr 26, 2021	BROIDRICK AMY S. EVP, Chief Strategy Officer · Director	Purchase	4,500	$2.03	$9K	4,500	Form 4
Apr 20, 2021	Poirier Michael S. Chairman, CEO & President · Director	Purchase	11,005	$1.80	$20K	11,005	Form 4
Apr 16, 2021	Lotz Christopher L. Vice President of Finance, CFO	Purchase	2,700	$1.86	$5K	12,541	Form 4
Dec 29, 2020	Kruger Kurt H Director	Purchase	4,000	$2.94	$12K	10,000	Form 4
Nov 23, 2020	Kruger Kurt H Director	Purchase	4,600	$3.46	$16K	6,000	Form 4
Nov 20, 2020	Kruger Kurt H Director	Purchase	1,400	$3.55	$5K	1,400	Form 4
May 22, 2020	Poirier Michael S. Chairman, President & CEO. · Director	Other	169,192	—	—	169,192	Form 4
May 22, 2020	Lotz Christopher L. VP of Finance, CFO.	Other	9,841	—	—	9,841	Form 4
Apr 10, 2020	FOEHR MATTHEW W Director	Award	38,461	—	—	138,635	Form 4
Jan 21, 2020	FOEHR MATTHEW W Director	Other	76,923	—	—	100,174	Form 4
Mar 12, 2020	Doyle Noah Director	Sale	500,000	$0.22	$110K	704,780	Form 4
Mar 4, 2020	Ritter Ira E. COB, CSO · Director	Sale	18,750	$0.38	$7K	81,727	Form 4
Mar 4, 2020	Ritter Andrew J CEO and President · Director	Sale	18,750	$0.38	$7K	81,727	Form 4
Feb 25, 2020	Doyle Noah Director	Option	500,000	$0.15	$75K	1,204,780	Form 4

Poirier Michael S.

Chairman and CEO

Purchase

Date

Jun 22

30,000

Price

$0.57

Value

$17K

View Form 4 on SEC.gov

BROIDRICK AMY S.

President/CSO

Purchase

Date

Jun 14

30,000

Price

$0.62

Value

$19K

View Form 4 on SEC.gov

Kruger Kurt H

Director

Purchase

Date

Aug 19

4,000

Price

$1.22

Value

$5K

View Form 4 on SEC.gov

Kruger Kurt H

Director

Purchase

Date

Aug 19

4,000

Price

$1.23

Value

$5K

View Form 4 on SEC.gov

BROIDRICK AMY S.

EVP, Chief Strategy Officer · Director

Purchase

Date

Apr 26

4,500

Price

$2.03

Value

$9K

View Form 4 on SEC.gov

Poirier Michael S.

Chairman, CEO & President · Director

Purchase

Date

Apr 20

11,005

Price

$1.80

Value

$20K

View Form 4 on SEC.gov

Lotz Christopher L.

Vice President of Finance, CFO

Purchase

Date

Apr 16

2,700

Price

$1.86

Value

$5K

View Form 4 on SEC.gov

Kruger Kurt H

Director

Purchase

Date

Dec 29

4,000

Price

$2.94

Value

$12K

View Form 4 on SEC.gov

Kruger Kurt H

Director

Purchase

Date

Nov 23

4,600

Price

$3.46

Value

$16K

View Form 4 on SEC.gov

Kruger Kurt H

Director

Purchase

Date

Nov 20

1,400

Price

$3.55

Value

$5K

View Form 4 on SEC.gov

Poirier Michael S.

Chairman, President & CEO. · Director

Other

Date

May 22

169,192

Price

—

Value

—

View Form 4 on SEC.gov

Lotz Christopher L.

VP of Finance, CFO.

Other

Date

May 22

9,841

Price

—

Value

—

View Form 4 on SEC.gov

FOEHR MATTHEW W

Director

Award

Date

Apr 10

38,461

Price

—

Value

—

View Form 4 on SEC.gov

FOEHR MATTHEW W

Director

Other

Date

Jan 21

76,923

Price

—

Value

—

View Form 4 on SEC.gov

Doyle Noah

Director

Sale

Date

Mar 12

500,000

Price

$0.22

Value

$110K

View Form 4 on SEC.gov

Ritter Ira E.

COB, CSO · Director

Sale

Date

Mar 4

18,750

Price

$0.38

Value

$7K

View Form 4 on SEC.gov

Ritter Andrew J

CEO and President · Director

Sale

Date

Mar 4

18,750

Price

$0.38

Value

$7K

View Form 4 on SEC.gov

Doyle Noah

Director

Option

Date

Feb 25

500,000

Price

$0.15

Value

$75K

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About QLGN insider trading

QLGN insider trades

Qualigen Therapeutics, Inc. (QLGN) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including QLGN. Over the past 12 months, 0 insiders have filed transactions with the SEC. QLGN insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Qualigen Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

QLGN insider trading · 5 questions

The insiders of Qualigen Therapeutics, Inc. (QLGN) include executives and directors such as QLGN, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

QLGN board member insider tradingwho are QLGN insidersQLGN insider rosterQualigen Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026